

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D5			
PMID #:	30444686			
Comments:	Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript. Blanks and '.' represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Variable Type	Label	Notes
1	EligPtTc	Num	Study eligibility flag	There are no ineligible patients
2	stage	Char	Stage per International Neuroblastoma Staging System	
3	risk_group	Char	Neuroblastoma risk group	1=Low; 2=Intermediate; 3=High
4	mycn	Char	MYCN gene status	
5	ploidy	Char	DNA index	Hypodiploid; Diploid; Hyperdiploid
6	histology	Char	International Neuroblastoma Pathology Classification (INPC)	1=Favorable; 2=Unfavorable
7	age_at_diag_vtb	Num	Age at neuroblastoma diagnosis	Units=days
8	sex_txt_vtb	Char	Patient gender	F=Female; M=Male
9	bio	Num	Biology based treatment assignment	0= 4S patients not assigned to 8 cycles based on biology; 1=eleven patients assigned to 8 cycles based on biology including LOH
10	efs_flag	Num	Neuroblastoma event flag	0=censor; 1=event
11	os_flag	Num	Overall Survival event flag	0=censor; 1=death

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D5			
PMID #:	30444686			
Comments:	Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript. Blanks and '.' represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
12	degrctntp	Char	Degree of resection	Complete/near-complete resection (>90%); Partial resection (50-90%); biopsy only (<50%)
13	STRATUM	Char	Stratum assignment	Group 2; Group 3; Group 4
14	efstime	Num	Time to neuroblastoma flag	Units=days
15	stime	Num	Time to Overall Survival flag	Units=days
16	Emergent_Therapy_per_ANBL0531_E	Char	Emergent therapy (per ANBL0531 Eligibility form) or symptomatic	
17	age_at_death	Num	Age at death	Units=days
18	bsln_evaluation_done	Num	Baseline evaluation	1=baseline evaluation done; 0=baseline evaluation not done
19	surgecklistatdx	Char	Surgical checklist done at diagnosis	
20	baseline_abnormality_g e3	Char	Presence of a baseline abnormality Grade 3 or higher	At least one Grade 3 or higher baseline abnormality; No Grade 3 or higher baseline abnormalities.
21	baseline_abnormality_g e4	Char	Presence of a baseline abnormality Grade 4 or higher	At least one Grade 4 or higher baseline abnormality; No Grade 4 or higher baseline abnormalities.
22	tbl3_death	Char	Death indicated in Table 3	

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D5			
PMID #:	30444686			
Comments:	<p>Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript. Blanks and '.' represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>			
23	ba_grd4_hyperbilirubinemia	Char	Grade 4 hyperbilirubinemia at baseline	
24	ba_grd4_hypofibrinogenemia	Char	Grade 4 hypofibrinogenemia at baseline	
25	GT50pct_resection	Char	Patient received greater than a 50% resection	
26	dth_hepatomegaly	Char	Death related to rapidly progressing hepatomegaly	
27	LIVER_RT	Char	Patient received radiation therapy to the liver	
28	b	Char	Biology	Favorable Biology; Unfavorable Biology
29	tbl2_symp_at_enroll	Char	Symptomatic at enrollment per Table 2	
30	tbl2_1p	Char	Chromosome arm 1p loss of heterozygosity per Table 2	No Loss of Heterozygosity (LOH); Loss of Heterozygosity (LOH)
31	tbl2_11q	Char	Chromosome arm 11q loss of heterozygosity per Table 2	No Loss of Heterozygosity (LOH); Loss of Heterozygosity (LOH)
32	first_5_deaths	Char	First five deaths on study	
33	fig_a1_enroll_post_prot_amend	Char	Figure A1 post protocol amendment enrollment	
34	Tbl2_dxproc	Char	Diagnostic procedure performed per Table 2	

Study Number:	ANBL0531			
NCT #:	NCT00499616			
Dataset #:	D5			
PMID #:	30444686			
Comments:	<p>Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript. Blanks and '.' represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>			
35	serious_surg_comp	Char	Patient had a serious surgical complication	
36	usi	Char	USI	Patient identifier and primary key
37	IdeSickBxIND_VTB	Num	Too sick for biopsy?	0=No; 1=Yes